Cablevision's support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research.

Research Awards Listing

Research follows dollars, and The Lustgarten Foundation believes that increasing funds for pancreatic cancer research will translate into enhanced patient care, and ultimately, a cure.

The Lustgarten Foundation firmly believes that increasing funds for pancreatic cancer research is the surest path to improved patient care and eventually, to a cure. To date, we have committed nearly $110 million to providing the best and brightest minds with the resources to pursue the study and eradication of the disease.

View Award Listings by Year

2014  |  2013  |  2012  |  2011  |  2010  | 2009  |  2008  | 2007  |  2006  |  2005  |  2004  |  2003  |  2002  |  2001  |  2000-1998

2014 Research Grant

Cold Spring Harbor Laboratory
David Tuveson, M.D., Ph.D.
Douglas Fearon

Cold Spring Harbor Laboratory 
Douglas Fearon, M.D.
Immunological Control of Pancreatic Cancer

Dana-Farber Cancer Institute
Massachusetts Institute of Technology
Charles Fuchs, M.D.
Mandar Muzumdar, M.D.
Obesity-Driven PDAC -- A Comprehensive Study to Define New Targets for Prevention and Therapy

Dana-Farber Cancer Institute
Robert Mayer, M.D.
Brian Wolpin, M.D., M.P.H.
Extension of Old Project - Metabolism with Matt Vander Heiden

Johns Hopkins Medical Institutes
Alison Klein, Ph.D.
Identification of Individuals at High Risk for Pancreatic Cancer

John Hopkins Medical Institutes
Bert Vogelstein, M.D.
Implying Cancer Genetics to Improve the Diagnosis, Prognosis and Treatment of Patients with Pancreatic Cancer.

Massachusetts Institute of Technology 
Hidde Ploegh, Ph.D.
Non-Invasive Monitoring of Inflammation and the Immune Response Against Pancreatic Cancer

Massachusetts Institute of Technology
Matt Vander Heiden, M.D., Ph.D.

Massachusetts Institute of Technology
Sangeeta Bhatia, M.D., Ph. D. 
Extension: Treatment of Pancreatic Cancer by Tumor-Penetrating Delivery of siRNA

Massachusetts Institute of Technology
Tyler Jacks, Ph.D.
Genome-Wide CRISPR-based Screens to Identify Unique Vulnerabilities in K-ras Dependent Pancreatic Cancer Cells

Memorial Sloan Kettering Cancer Center
Scott Lowe, Ph.D.
Target Identification and Validation in Pancreatic Ductal Adenocarcinoma

Memorial Sloan Kettering Cancer Center
Steve Leach,M.D.
Large-Scale, Systemic Evaluation of Combination Therapies for Pancreatic Ductal Adenocarcinoma

Salk Institute for Biological Studies
Ron Evans, Ph.D.
Curing Pancreatic Cancer Through Epigentic Reprogramming
Interdicting Reciprocal Cytokine Interactions Between Pancreatic Stellate Cells and Pancreatic Tumor

Stanford University
Julien Sage, Ph.D 
Protein Methyltransferase Signaling -- Discovery of Novel Therapeutic Targets in Pancreatic Cancer

University and Hospital Trust of Verona
Aldo Scarpa, M.D., Ph.D.

University of California, San Francisco
Frank McCormick, Ph.D
New Ways of Treating Pancreatic Cancer Based on Reversing K-Ras Mediated Stemness

University of Indiana
Max Schmidt, M.D., Ph.D.

University of Michigan
Diane Simeone, M.D.
Personalized Theraputics Using a Novel Circultaing Tumor Cell Ex Vivo Expansion Model

University of North Carolina
Channing Der, Ph.D.
Identification and Validation of RAF Inhibitor-based combination K-Ras Targeted Therapies

University of Pittsburgh
Randal Brand, M.D.

Vanderbilt University
Stephen Fesik, Ph.D.
Discovery of Small Molecules that Target the RAS/SOS Complex for the Treatment of Pancreatic Cancer

Weill Cornell Medical Center
Lewis Cantley, Ph.D.
Targeting PIP4K2A/B for Pancreatic Cancer Therapy

Elizabeth Jaffee, M.D., Johns Hopkins Medical Institutions

“As a result of Lustgarten Foundation funding, we were able to produce enough vaccine to test our potential therapy in pancreatic cancer patients. Without this funding, we would not have been able to conduct this trial.”
-  Elizabeth Jaffee, M.D., Johns Hopkins Medical Institutions

2015 website development and design sponsored by Celgene

1111 Stewart Avenue, Bethpage, New York 11714
Toll Free: 1-866-789-1000 P: 516-803-2304 F: 516-803-2303